gefitinib has been researched along with hematoporphyrin in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (hematoporphyrin) | Trials (hematoporphyrin) | Recent Studies (post-2010) (hematoporphyrin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 2,020 | 43 | 202 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, H; Gao, Y; Li, X; Li, Z; Wang, J; Xu, L; Zhu, F | 1 |
2 other study(ies) available for gefitinib and hematoporphyrin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Co-delivery of gefitinib and hematoporphyrin by aptamer-modified fluorinated dendrimer for hypoxia alleviation and enhanced synergistic chemo-photodynamic therapy of NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dendrimers; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hematoporphyrins; Humans; Hypoxia; Lung Neoplasms; Mutation; Photochemotherapy; Protein Kinase Inhibitors; Tumor Microenvironment | 2021 |